Skip to main content
. 2023 Jan 30;15(2):455. doi: 10.3390/pharmaceutics15020455

Figure 3.

Figure 3

UMBO increased the efficacy of anti-PD-L1 in GL261-bearing mice. (Panel A): shows a timeline of the treatment protocol used in the survival experiments. Cell grafting was done on day 1 while treatments were applied on days 14, 18, 24, and 28. Mice were followed up for 100 days. (Panel B,C): (Panel B): bioluminescence normalized to the first measured value after cell inoculation in GL261-bearing mice. Each dot represents values for one animal and the line represents the median value for the group. Bioluminescence signal was measured weekly. Dotted lines represent the days of treatments. Anti PD-L1 plus UMBO suppressed tumor growth over time compared to controls. ** for p ≤ 0.01. Repeated UMBO alone does not affect OS (Panel C) or body weight (Supplementary Material, Figure S4) in GL261-bearing mice compared to the non-treated (Panel C). (Panel C): UMBO plus an-ti-PD-L1 increased OS (* p < 0.05) compared to anti-PD-L1 alone and (*** p < 0.0001) compared to control groups.